purpos
review
precis
medicin
pm
repres
new
paradigm
diseas
diagnosi
prevent
treatment
pm
approach
focus
character
differ
phenotyp
pathogen
pathway
order
allow
select
specif
biomark
use
diseas
manag
rhiniti
highli
preval
heterogen
diseas
term
underli
endotyp
clinic
present
therefor
appli
pm
principl
variou
rhiniti
subtyp
rise
meaning
strategi
improv
evalu
treatment
recent
find
technolog
recombin
allergen
allow
molecular
character
ige
reactiv
specif
individu
compon
allergen
extract
recent
publish
ongo
clinic
trial
base
compon
resolv
diagnosi
crd
bring
precis
allergen
immunotherapi
allerg
rhiniti
monoclon
antibodi
variou
cytokin
involv
inflammatori
allerg
nonallerg
rhiniti
endotyp
show
promissori
result
summari
better
understand
pathogen
pathway
togeth
accur
phenotyp
classif
patient
present
rhiniti
symptom
contribut
point
clinic
use
biomark
diagnost
tool
lead
accur
environment
control
measur
person
pharmacolog
option
new
biolog
therapi
develop
precis
medicin
pm
grow
new
paradigm
diseas
manag
pm
draw
recent
advanc
omic
scienc
molecular
biolog
bioinformat
appli
evalu
treatment
health
disord
base
knowledg
pathophysiolog
mechan
endotyp
variou
clinic
express
phenotyp
diseas
pm
seek
identifi
best
manag
strategi
allow
arriv
accur
diagnosi
turn
facilit
predict
prevent
therapeut
approach
adjust
characterist
need
patient
promot
activ
particip
decisionmak
three
step
pm
pathophysiolog
identif
molecular
mechan
diseas
variant
predictiondiagnosi
identif
biomark
specif
diagnost
tool
manag
blockinginterfer
mechan
prevent
andor
treatment
multifactori
chronic
inflammatori
disord
upper
airway
multipl
variant
rhiniti
endotyp
phenotyp
usual
overlap
dynam
render
clearcut
differenti
difficult
appli
pm
approach
heterogen
group
diseas
acquir
potenti
greater
relev
articl
discuss
present
knowledg
incom
develop
step
pm
approach
rhiniti
evalu
manag
chronic
rhiniti
one
preval
patholog
condit
upper
airway
usual
present
frequent
comorbid
condit
associ
consider
impact
qualiti
life
financi
burden
health
care
system
rhiniti
character
nasal
congestionobstruct
anterior
posterior
rhinorrhea
sneez
itch
howev
high
variabl
underli
pathophysiolog
mechan
clinic
phenotyp
three
wide
accept
rhiniti
subgroup
thu
far
allerg
rhiniti
ar
infecti
rhiniti
nonallerg
noninfecti
rhiniti
nar
last
one
recogn
wide
rang
underli
pathophysiolog
mechan
relev
pathophysiolog
mechan
involv
type
subtyp
rhiniti
tabl
well
potenti
biomark
endotyp
briefli
discuss
process
antigenpres
cell
nasal
mucosa
present
lymphocyt
initi
sensit
respons
character
interleukin
il
product
cytokin
induc
differenti
b
lymphocyt
plasma
cell
lead
product
allergenspecif
ige
turn
bind
highaffin
ige
receptor
surfac
mast
cell
basophil
aeroallergen
reexposur
crosslink
specif
ige
molecul
allergen
peptid
lead
mast
cell
basophil
degranul
preform
ie
histamin
newli
form
mediat
ie
leukotrien
prostaglandin
plateletactiv
factor
main
respons
immedi
within
min
allerg
symptom
mani
case
latephas
reaction
took
place
h
later
due
releas
chemokin
chemoattract
induc
cell
activ
eosinophil
mast
cell
migrat
nasal
epithelium
releas
addit
cytokin
mediat
enzym
caus
delay
allerg
symptom
perpetu
allerg
inflamm
despit
igemedi
inflammatori
endotyp
ar
seem
suffici
clear
result
phenotyp
show
multipl
express
aria
guidelin
categor
ar
durat
either
intermitt
g
day
per
week
g
week
persist
day
per
week
week
sever
mild
character
normal
sleep
neither
impair
daili
activ
troublesom
symptom
moderatesever
associ
impair
work
leisur
sport
school
daili
activ
troublesom
symptom
although
aria
classif
could
certainli
use
term
ar
manag
gener
practition
consid
relev
allergen
allergen
respons
sensit
trigger
symptom
patient
might
meaning
pm
approach
term
diagnost
precis
secondari
prevent
person
treatment
follow
molecular
character
ige
reactiv
specif
individu
compon
allergen
extract
possibl
due
technolog
recombin
allergen
identif
immunoreact
singl
allergen
compon
allerg
individu
allow
specif
defin
patient
allerg
profil
obtain
soterm
compon
resolv
diagnosi
crd
local
allerg
rhiniti
also
call
entop
rhiniti
distinct
phenotyp
character
presenc
nasal
symptom
ar
nonatop
patient
neg
skin
prick
test
spt
undetect
serumspecif
ige
inhal
allergen
posit
nasal
allergen
provoc
test
napt
local
allerg
rhiniti
lar
form
chronic
rhiniti
local
antigenspecif
ige
product
common
aeroallergen
hous
dust
mite
grass
pollen
mechan
lar
impli
allergen
exposur
nasal
ar
allerg
rhiniti
lar
local
allerg
rhiniti
crssnp
chronic
rhinosinus
without
nasal
polyp
crswnp
chronic
rhinosinus
nasal
polyp
nare
nonallerg
rhiniti
eosinophilia
syndrom
seig
specif
ige
aureu
enterotoxin
e
bat
basophil
activ
test
napt
nasal
allergen
provoc
test
nno
nasal
nitric
oxid
ecp
eosinophil
cation
protein
mpo
myeloperoxidas
mucos
product
specif
ige
local
inflammatori
respons
nowaday
clinic
practic
effort
endotyp
patient
rhiniti
mainli
limit
measur
total
allergenspecif
ige
level
eosinophil
cation
protein
ecp
blood
nasal
eosinophil
count
sensit
test
ar
base
demonstr
allergenspecif
ige
posit
spt
allergen
provid
indirect
evid
allergenspecif
ige
cutan
mast
cell
spt
robust
easytous
screen
instrument
common
allergen
sourc
serolog
vitro
diagnost
test
altern
option
provid
direct
assess
circul
allergenspecif
ige
recent
suggest
detect
serum
ige
specif
molecul
phl
p
phl
p
bet
v
pru
p
may
also
use
biomark
predict
season
allerg
rhiniti
persist
futur
onset
comorbid
asthma
andor
oral
allergi
syndrom
case
extrem
low
total
serum
ige
level
basophil
activ
test
bat
allow
highli
sensit
indirect
demonstr
allergenspecif
ige
surfac
human
effector
cell
fresh
blood
bat
nasalspecif
ige
quantif
use
test
diagnosi
lar
nasal
allergen
provoc
test
napt
capabl
differenti
allerg
ar
lar
nonallerg
individu
healthi
control
nar
well
relev
nonrelev
allergen
sensit
atop
subject
nitric
oxid
found
involv
inflamm
induc
regulatori
protect
defens
tissuedamag
effect
chemiluminesc
repres
gold
standard
nasal
nno
measur
nasal
devic
increas
level
exhal
nno
found
patient
ar
compar
normal
subject
rhiniti
frequent
coexist
sinus
nose
sinus
share
vascular
neuron
anatom
pathway
acut
rhinosinus
predominantli
viral
origin
usual
caus
rhinoviru
coronaviru
adenoviru
parainfluenza
viru
respiratori
syncyti
viru
enteroviru
viral
rhinosinus
may
complic
secondari
bacteri
superinfect
ie
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
establish
bacteri
rhinosinus
endotyp
chronic
rhinosinus
character
nasal
congest
purul
discharg
facial
pain
last
longer
week
presenc
absenc
nasal
polyp
allow
phenotyp
classif
chronic
rhinosinus
without
nasal
polyp
chronic
rhinosinus
without
nasal
polyp
crssnp
seem
involv
mucos
inflamm
overexpress
transform
growth
factor
beta
result
tissu
remodel
neutrophil
infiltr
nasal
biopsi
sampl
well
nasal
fluid
mpo
might
consid
potenti
biomark
contrast
endotyp
chronic
rhinosinus
nasal
polyp
crswnp
seem
driven
character
increas
level
manifest
signific
mucos
eosinophilia
increas
level
total
specif
ige
microbi
superantigen
staphylococcu
aureu
toxin
might
also
play
role
throughout
basophil
degranul
interact
cell
receptor
specif
ige
aureu
enterotoxin
e
se
latter
one
consid
specif
biomark
crswnp
hand
reduct
nno
level
demonstr
patient
crswnp
compar
patient
crssnp
tabl
although
question
defin
someth
nar
compris
heterogen
group
nasal
condit
affect
million
individu
worldwid
review
focu
subtyp
pm
provid
greater
benefit
nonallerg
rhiniti
eosinophilia
syndrom
nare
origin
defin
presenc
eosinophil
nasal
smear
without
evid
igemedi
sensit
anosmia
distinct
characterist
present
ar
patient
nare
also
risk
factor
develop
nasal
polyposi
aspirin
sensit
bronchial
hyperreact
nonallerg
asthma
pathophysiolog
poorli
understood
key
compon
involv
selfperpetu
chronic
eosinophil
nasal
inflamm
contribut
direct
mucos
damag
protract
mucociliari
clearanc
nasal
hyperrespons
granul
eosinophil
contain
toxic
basic
protein
major
eosinophil
cation
protein
ecp
constitut
wellstandard
marker
tissu
eosinophilia
activ
ecp
level
nasal
secret
use
monitor
eosinophil
inflamm
differ
kind
rhiniti
eosinophil
involv
constitut
indic
efficaci
treatment
nare
associ
local
allergi
entopi
local
inflamm
driven
staphylococcu
aureu
enterotoxin
idiopath
rhiniti
ir
preval
subtyp
nar
group
also
diagnosi
requir
exclus
ar
nasal
eosinophilia
structur
defect
underli
system
diseas
absenc
cellular
inflammatori
pattern
pathophysiolog
mechan
ir
like
neurogen
mediat
common
trigger
symptom
includ
chemic
irrit
tobacco
smoke
perfum
clean
agent
also
chang
temperatur
humid
barometr
pressur
well
alcohol
ingest
neural
vascular
pathophysiolog
mechan
initi
propos
explain
effect
nonspecif
irrit
alcohol
induc
tachykinin
releas
inhibit
sympathet
mediat
enhanc
parasympathet
respons
therefor
end
nasal
congest
andor
rhinorrhea
anoth
group
evid
suggest
ir
may
disord
nonadrenerg
noncholinerg
peptiderg
neural
system
nasal
peptiderg
neuron
mainli
sensori
c
fiber
activ
nonspecif
stimuli
result
antidrom
orthodrom
releas
inflammatori
neuropeptid
exert
effect
blood
vasculatur
mucussecret
gland
lead
symptom
ir
neurogen
rhiniti
endotyp
could
also
help
explain
gustatori
rhiniti
rhiniti
elderli
well
featur
acut
viral
rhiniti
cold
air
respons
even
ar
neural
inflamm
lead
nonspecif
hyperreact
rhiniti
elderli
commonli
present
profus
rhinorrhea
attribut
nasal
hyperrespons
parasympathet
system
gustatori
rhiniti
defin
acut
onset
profus
wateri
rhinorrhea
immedi
ingest
certain
spici
food
act
eat
also
associ
overstimul
parasympathet
system
sever
biomark
might
use
mainli
research
set
substanc
p
neurokinin
stain
mucos
biopsi
specimen
transient
receptor
potenti
cation
channel
subfamili
v
member
also
known
capsaicin
receptor
zonula
occluden
occlud
use
similar
purpos
hormon
rhiniti
subtyp
includ
rhiniti
pregnanc
menstrual
cyclerel
rhiniti
rhiniti
pregnanc
typic
begin
week
gestat
resolv
spontan
within
week
postpartum
wherea
menstrual
cyclerel
rhiniti
consist
symptom
appear
last
day
menstrual
cycl
subjac
endotyp
might
primarili
mediat
either
increas
level
estrogen
caus
nasal
congest
vascular
engorg
vasodil
effect
progesteron
mechan
also
suggest
includ
increas
product
human
growth
hormon
enhanc
product
placent
growth
hormon
variant
prolactin
pathophysiolog
perspect
system
druginduc
rhiniti
may
classifi
three
subtyp
local
inflammatori
neurogen
idiopath
type
prototyp
inflammatori
endotyp
repres
aspirinexacerb
respiratori
diseas
aerd
condit
character
hypersensit
aspirin
nonsteroid
antiinflammatori
drug
lead
upper
lower
airway
inflamm
result
sever
rhinosinus
asthma
symptom
inhibit
shift
metabol
arachidon
acid
lipooxygenas
pathway
result
increas
cysteinyl
leukotrien
releas
precipit
local
inflamm
diagnosi
nar
base
detail
medic
histori
exclus
clinic
relev
sensit
airborn
allergen
exclus
clinic
sign
rhinosinus
absenc
atopi
neg
spt
increas
nasal
eosinophil
count
higher
baselin
level
urinari
lte
would
consid
specif
biomark
aerd
alphaadrenerg
betaadrenerg
antagonist
clonidin
methyldopa
could
mediat
symptom
rhiniti
throughout
neurogen
endotyp
downregul
sympathet
tone
lead
vascular
engorg
nasal
congest
rhinorrhea
select
inhibitor
sildenafil
tadalafil
vardenafil
act
vasodil
properti
erectil
tissu
nasal
turbin
exampl
neurogen
endotyp
ace
inhibitor
result
increas
releas
bradykinin
potent
vasodil
might
also
includ
subtyp
drug
eg
betablock
calcium
channel
blocker
antipsychot
could
induc
rhiniti
still
unknown
pathophysiolog
mechan
idiopath
endotyp
rhiniti
medicamentosa
defin
rebound
nasal
congest
follow
excess
local
use
decongest
spray
nasal
vasoconstrictor
like
sympathomimet
imidazolin
also
coacain
main
respons
drug
diagnosi
lie
clinic
histori
physic
examin
swollen
red
nasal
mucou
membran
minim
discharg
manag
seem
obviou
pathophysiolog
mechan
merit
discuss
workrel
rhiniti
includ
develop
nasal
symptom
caus
factor
work
environ
well
workexacerb
rhiniti
preexist
concurr
rhiniti
worsen
occup
factor
natur
workplac
airborn
agent
exposur
pathophysiolog
mechan
involv
may
distinguish
allerg
nonallerg
endotyp
highmolecularweight
agent
anim
rodent
protein
lowmolecularweight
agent
platinum
salt
complet
antigen
capabl
elicit
specif
igemedi
respons
other
lowmolecularweight
agent
diisocyan
trimellit
acid
act
hapten
need
bind
endogen
protein
order
initi
specif
igemedi
respons
hand
singl
exposur
high
chemic
irrit
concentr
multipl
exposur
lower
chemic
irrit
concentr
time
chlorin
sulfur
dioxid
ammonia
lead
signific
inflamm
even
structur
damag
irritantmedi
nonallerg
endotyp
term
reactiv
upper
airway
dysfunct
syndrom
irritantinduc
rhiniti
corros
rhiniti
depend
sever
long
last
process
scarciti
specif
biomark
nar
reinforc
need
implement
complementari
evalu
tool
nasal
flow
measur
confirm
nasal
obstruct
cold
dri
air
provoc
search
nasal
hyperreact
nno
measur
evalu
nasal
inflamm
test
smell
perform
nare
patient
mention
reduc
smell
capac
nasofibroscopi
axial
comput
tomographi
help
evalu
anatom
alter
presenc
chronic
rhinosinus
without
polyp
evid
atroph
rhiniti
patient
moderatetosever
rhiniti
inadequ
control
despit
treatment
accord
current
rhiniti
manag
guidelin
fig
precis
medicin
approach
rhiniti
evalu
manag
nhr
nasal
hyperreact
nno
nasal
nitric
oxid
act
axial
comput
tomographi
spt
skin
prick
test
ecp
eosinophyl
cation
protein
hmw
high
molecular
weight
ar
allerg
rhiniti
aria
allerg
rhiniti
impact
asthma
guid
napt
nasal
allergen
provoc
test
ait
allergen
immunotherapi
nar
nonallerg
rhiniti
nare
nonallerg
rhiniti
eosinophilia
syndrom
crswnp
chronic
rhinosinus
nasal
polyp
crssnp
chronic
rhinosinus
without
nasal
polyp
siges
specif
ige
aureu
enterotoxin
e
mpo
myeloperoxidas
sp
substanc
p
transient
receptor
potenti
cation
channel
subfamili
v
member
leukotrien
aerd
aspirinexacerb
respiratori
diseas
mab
monoclon
antibodi
asterisk
indic
mab
target
cytokin
dupilumab
via
block
receptor
alpha
mepolizumab
receptor
alpha
benralizumab
well
ige
omalizumab
neg
impact
daili
function
risk
develop
seriou
comorbid
asthma
chronic
rhinosinus
pm
strategi
base
endotypedriven
manag
repres
futur
rhiniti
care
patient
whose
symptom
fulli
control
despit
evidencebas
treatment
current
definit
rhiniti
reli
combin
histori
physic
examin
allergi
diagnost
test
allow
distinct
previous
state
three
major
subgroup
allerg
infecti
nonallerg
noninfecti
rhiniti
first
step
implement
pm
patient
rhiniti
character
endotyp
guid
tailor
manag
approach
furthermor
keep
mind
sever
modul
endotyp
express
environ
microbiom
lifestyl
nasal
anatomi
best
exampl
endotypedriven
treatment
ar
use
allergenspecif
immunotherapi
patient
allergeninduc
type
immun
respons
endotyp
lead
clinic
relev
exposuresymptom
relat
exampl
aim
interfer
type
immun
respons
includ
biolog
treatment
monoclon
antibodi
target
either
receptor
crswnp
hand
nar
phenotyp
warrant
differ
treatment
strategi
depend
known
suspect
underli
etiolog
inflamm
neurogen
dysfunct
environment
exposur
andor
medic
use
allergen
immunotherapi
ait
repres
import
intervent
current
adjunct
pharmacolog
treatment
confer
specif
advantag
convent
manag
decis
prescrib
ait
patient
individu
base
clinic
relev
allergen
persist
symptom
despit
appropri
medic
accord
guidelin
well
avail
goodqual
efficaci
extract
current
avail
valid
biomark
predict
ait
success
first
premis
prescript
immunotherapi
base
crd
assess
ige
posit
genuin
versu
crossreact
allergen
precis
identif
relev
sensit
case
pollenallerg
patient
monosensit
oligosensit
pollen
overlap
pollen
season
achiev
convent
diagnosi
complet
pollen
extract
case
patient
sensit
major
pollen
allergen
may
case
area
high
pollen
load
prescrib
ait
area
high
frequenc
sensit
minor
allergen
molecular
diagnosi
may
special
interest
sinc
commerci
extract
immunotherapi
well
standard
major
allergen
thu
patient
sensit
minor
allergen
alon
may
like
receiv
suffici
amount
antigen
achiev
success
outcom
ait
even
wors
experi
advers
reaction
concentr
minor
allergen
present
extract
high
addit
ait
would
appropri
prescrib
sensit
speciesspecif
allergen
confirm
pollen
allergi
case
select
recognit
crossreact
allergen
like
profilin
polcalcin
call
panallergen
highli
conserv
structur
ubiquit
distribut
molecul
among
plant
speci
crossreact
carbohydr
determin
present
glycoprotein
virtual
pollen
indic
ait
arguabl
crossreact
allergen
seem
limit
clinic
relev
besid
content
ait
extract
usual
quantifi
although
biolog
agent
studi
treatment
patient
ar
none
current
approv
treatment
ar
alon
omalizumab
human
antiig
monoclon
antibodi
bind
free
ige
prevent
bind
receptor
mast
cell
basophil
agent
also
decreas
ige
receptor
effector
cell
metaanalysi
random
clinic
trial
rct
assess
efficaci
safeti
omalizumab
poorli
control
allerg
rhiniti
includ
studi
patient
conclud
omalizumab
significantli
associ
symptom
relief
decreas
rescu
medic
use
improv
qualiti
life
probabl
due
high
cost
omalizumab
use
monotherapi
treatment
ar
may
consid
combin
ait
highli
sensit
polyallerg
rhiniti
patient
increas
risk
anaphylaxi
monoclon
antibodi
propos
novel
therapi
patient
suffer
crswnp
two
recent
metaanalys
antiig
therapi
omalizumab
assess
two
studi
antiinterleukin
therapi
three
studi
one
reslizumab
two
mepolizumab
dupilumbab
therapi
three
studi
biolog
therapi
prove
effect
reduc
total
nasal
endoscop
polyp
score
improv
sever
outcom
opacif
comput
tomographi
qualiti
life
measur
nasal
airflow
olfact
type
associ
biomark
recent
addon
dupilumab
inhal
corticosteroid
result
signific
clinic
meaning
improv
endoscop
radiolog
clinic
patientreport
sinonas
asthma
outcom
patient
crswnp
biolog
agent
target
appear
promissori
macrolid
antibiot
demonstr
great
benefit
crssnp
use
antiinflammatori
immunomodulatori
properti
includ
blockag
proinflammatori
cytokin
tumor
necrosi
preval
ar
well
allerg
diseas
increas
least
five
decad
possibl
caus
increas
could
exposur
genet
predispos
individu
constantli
chang
indoor
outdoor
environ
two
chang
strongli
implic
sensit
process
trigger
symptom
allerg
diseas
air
pollut
global
warm
induc
climat
chang
factor
close
relat
experiment
epidemiolog
studi
shown
posit
correl
climat
chang
air
pollut
incid
respiratori
allerg
diseas
therefor
expect
intervent
done
improv
environ
would
benefit
gener
popul
larg
patient
ar
could
reduc
possibl
develop
allerg
diseas
facilit
treatment
improv
qualiti
life
patient
home
environment
intervent
acaricid
bedroom
control
program
may
benefit
reduc
dust
mite
load
rhiniti
symptom
one
main
problem
achiev
effect
erad
allergen
lie
adher
complianc
recommend
measur
sinc
may
requir
modif
hous
control
moistur
sourc
control
pet
insect
improv
ventil
hous
among
other
regard
gener
extern
environ
clear
depend
mainli
state
polici
tend
modifi
behavior
action
individu
recycl
organ
materi
use
biodegrad
product
etc
gener
popul
emiss
control
gase
promot
develop
nonpollut
energi
activ
control
construct
healthi
home
use
pesticid
emiss
gase
industri
activ
etc
holist
chang
lifestyl
impact
global
health
human
patient
ar
avoid
etiolog
agent
prefer
manag
option
mani
patient
neurogen
inflammationdriven
endotyp
occup
rhiniti
gustatori
rhiniti
neuron
imbal
rhiniti
medicamentosa
irrit
avoid
smoke
stop
advis
rhiniti
patient
way
treatment
druginduc
phenotyp
nar
primarili
consist
avoid
drug
aspirinintoler
individu
may
benefit
aspirin
desensit
inflammatori
group
occup
rhiniti
druginduc
rhiniti
may
benefit
antiinflammatori
treatment
nasal
corticosteroid
nasal
antihistamin
treatment
noninflammatori
phenotyp
nar
divers
depend
presum
pathophysiolog
ipratropium
bromid
anticholinerg
drug
first
treatment
option
rhiniti
elderli
anoth
exampl
endotypedriven
treatment
highli
success
intervent
capsaicin
neurogen
noninflammatori
endotyp
capsaicin
treatment
patient
ir
produc
symptomat
relief
reduc
express
transient
receptor
potenti
cation
channel
subfamili
v
receptor
capsaicin
alter
nasal
epitheli
morpholog
induc
apoptosi
necrosi
cultur
human
nasal
epitheli
cell
mast
cell
sinc
mani
year
use
azelastin
found
effect
nar
patient
recent
azelastin
demonstr
exhibit
channel
activ
modul
signal
sensori
neuron
nasal
epitheli
cell
precis
medicin
impli
incorpor
wide
array
individu
data
includ
clinic
lifestyl
genet
biomark
inform
pm
focus
stratif
patient
beyond
classic
signsandsymptom
approach
identifi
modifi
trait
treat
better
way
precis
valid
phenotyp
recognit
due
better
understand
critic
causal
pathway
although
often
underestim
rhiniti
one
common
chronic
diseas
worldwid
increas
preval
morbid
greater
impact
qualiti
life
recent
new
initi
launch
field
pm
aim
promot
circul
knowledg
field
person
predict
prevent
participatori
medicin
field
allerg
diseas
respiratori
medicin
impera
three
wide
accept
rhiniti
subgroup
thu
far
infecti
rhiniti
ar
nar
underli
mechan
numer
divers
diseas
phenotyp
larg
overlap
make
clear
demarc
challeng
pm
approach
rhiniti
evalu
manag
schemat
summar
fig
first
step
base
medic
histori
physic
examin
search
environment
exposur
lifestyl
second
step
includ
basic
laboratori
test
nasal
structur
function
evalu
character
deep
evalu
requir
identif
specif
biomark
mainli
avail
research
set
third
step
consist
implement
specif
prevent
measur
endotypedriven
therapeut
option
greatest
advanc
made
field
ait
inhibit
blockad
molecul
associ
immun
mediat
endotyp
howev
studi
still
mandatori
phenotyp
associ
neurogen
idiopath
endotyp
conflict
interest
carlo
crisci
declar
conflict
interest
ledit
ardusso
declar
conflict
interest
articl
contain
studi
human
anim
subject
perform
author
